Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma (Abstract LBA8).
Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.
Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer by lines of prior chemotherapy (Abstract 932PD).
Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized prostate cancer patients who relapsed after radical prostatectomy and/or radiotherapy (Abstracts LBA31, 783O, 784O).
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolumab or ipilimumab alone (Abstract 1213O).
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) for biliary tract cancer (LBA29).
